Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTB NASDAQ:DERM NASDAQ:EDSA NASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$2.41+2.8%$2.73$0.70▼$3.82$135.93M-0.21196,742 shs12,525 shsDERMJourney Medical$4.91-1.8%$5.99$4.31▼$9.56$133.73M1.03188,661 shs20,918 shsEDSAEdesa Biotech$14.70-3.8%$7.67$0.72▼$20.32$130.16M1.263.22 million shs90,239 shsSNSESensei Biotherapeutics$20.95+1.1%$29.66$5.25▼$36.76$28.09M-0.18229,290 shs10,540 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma-0.85%-5.26%-17.02%-11.70%+188.96%DERMJourney Medical-1.38%-3.66%-3.29%-38.27%-27.33%EDSAEdesa Biotech-6.26%-13.13%+176.81%+1,355.24%+645.37%SNSESensei Biotherapeutics-11.41%-23.11%-30.65%+135.03%+187.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$2.41+2.8%$2.73$0.70▼$3.82$135.93M-0.21196,742 shs12,525 shsDERMJourney Medical$4.91-1.8%$5.99$4.31▼$9.56$133.73M1.03188,661 shs20,918 shsEDSAEdesa Biotech$14.70-3.8%$7.67$0.72▼$20.32$130.16M1.263.22 million shs90,239 shsSNSESensei Biotherapeutics$20.95+1.1%$29.66$5.25▼$36.76$28.09M-0.18229,290 shs10,540 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma-0.85%-5.26%-17.02%-11.70%+188.96%DERMJourney Medical-1.38%-3.66%-3.29%-38.27%-27.33%EDSAEdesa Biotech-6.26%-13.13%+176.81%+1,355.24%+645.37%SNSESensei Biotherapeutics-11.41%-23.11%-30.65%+135.03%+187.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 2.80Moderate Buy$8.67260.36% UpsideDERMJourney Medical 2.40Hold$13.00164.77% UpsideEDSAEdesa Biotech 2.00Hold$5.00-66.00% DownsideSNSESensei Biotherapeutics 2.00Hold$40.0090.93% UpsideCurrent Analyst Ratings BreakdownLatest SNSE, EDSA, CNTB, and DERM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026CNTBConnect Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/24/2026SNSESensei Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SNSESensei Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/20/2026DERMJourney Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026SNSESensei Biotherapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$50.003/31/2026CNTBConnect Biopharma BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/27/2026EDSAEdesa Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026DERMJourney Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$60K2,265.51N/AN/A$0.75 per share3.21DERMJourney Medical$61.86M2.17N/AN/A$0.96 per share5.11EDSAEdesa BiotechN/AN/AN/AN/A$0.45 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$14.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$55.48M-$1.00N/AN/AN/AN/A-88.21%-74.26%5/21/2026 (Estimated)DERMJourney Medical-$11.43M-$0.47N/A3.56N/A-18.48%-46.40%-13.22%5/13/2026 (Estimated)EDSAEdesa Biotech-$7.19M-$1.15N/AN/AN/AN/A-163.57%-52.54%5/13/2026 (Estimated)SNSESensei Biotherapeutics-$21.08M-$16.67N/AN/AN/AN/A-83.59%-69.97%5/12/2026 (Estimated)Latest SNSE, EDSA, CNTB, and DERM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026CNTBConnect Biopharma-$0.29N/AN/AN/AN/AN/A5/13/2026Q1 2026DERMJourney Medical-$0.07N/AN/AN/A$15.47 millionN/A5/13/2026N/AEDSAEdesa Biotech-$0.24N/AN/AN/AN/AN/A5/12/2026Q4 2025SNSESensei Biotherapeutics-$0.62N/AN/AN/AN/AN/A3/31/2026Q4 2025CNTBConnect Biopharma-$0.30-$0.27+$0.03-$0.27$0.00 million($0.05) million3/30/2026Q4 2025SNSESensei Biotherapeutics-$4.81-$3.74+$1.07-$3.74($4.85) millionN/A3/25/2026Q4 2025DERMJourney Medical-$0.06-$0.04+$0.02-$0.04$18.86 million$16.08 million2/13/2026Q1 2026EDSAEdesa Biotech-$0.28-$0.28N/A-$0.28N/A$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect Biopharma0.013.743.74DERMJourney Medical0.791.791.53EDSAEdesa BiotechN/A16.8216.82SNSESensei BiotherapeuticsN/A5.065.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%DERMJourney Medical7.25%EDSAEdesa Biotech5.50%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%DERMJourney Medical15.03%EDSAEdesa Biotech24.40%SNSESensei Biotherapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11056.52 million43.75 millionOptionableDERMJourney Medical9027.33 million23.22 millionN/AEDSAEdesa Biotech208.89 million6.72 millionNot OptionableSNSESensei Biotherapeutics401.34 million1.03 millionNot OptionableSNSE, EDSA, CNTB, and DERM HeadlinesRecent News About These CompaniesSensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street AnalystsMay 5, 2026 | finance.yahoo.comSensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast CancerMay 5, 2026 | businesswire.comSensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00April 28, 2026 | msn.comSensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 9, 2026 | businesswire.comSensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdateMarch 30, 2026 | businesswire.comSensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 25, 2026 | businesswire.comMerger deal renews Faeth in Sensei; Piktor brightens, stock jumpsFebruary 18, 2026 | bioworld.comBSensei Biotherapeutics stock soars after Faeth Therapeutics acquisitionFebruary 18, 2026 | investing.comSensei Biotherapeutics stock soars 230% after Faeth dealFebruary 18, 2026 | msn.comSensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private PlacementFebruary 18, 2026 | finance.yahoo.comSNSE stock surges to 21-month high – everything to know about its Faeth Therapeutics acquisitionFebruary 18, 2026 | msn.comSensei Biotherapeutics Expands Board, Adds Finance ExpertiseFebruary 13, 2026 | tipranks.comSensei Biotherapeutics Inc.February 1, 2026 | wsj.comEgle Therapeutics Appoints John Celebi as Chief Executive OfficerJanuary 7, 2026 | globenewswire.comSensei Biotherapeutics updates executive retention and compensation agreementsDecember 23, 2025 | msn.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder James Peyer Sells 3,105 SharesDecember 11, 2025 | insidertrades.comJames Peyer Sells 5,000 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) StockDecember 9, 2025 | insidertrades.comWhat Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump?December 5, 2025 | benzinga.comSensei Biotherapeutics Reports Strategic Shift in Q3 2025November 14, 2025 | tipranks.comSensei Biotherapeutics Reports Third Quarter 2025 Financial ResultsNovember 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNSE, EDSA, CNTB, and DERM Company DescriptionsConnect Biopharma NASDAQ:CNTB$2.40 +0.07 (+2.78%) As of 10:58 AM Eastern This is a fair market value price provided by Massive. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Journey Medical NASDAQ:DERM$4.91 -0.09 (-1.80%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Edesa Biotech NASDAQ:EDSA$14.70 -0.58 (-3.77%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Sensei Biotherapeutics NASDAQ:SNSE$20.95 +0.22 (+1.06%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
